Literature DB >> 15090840

Are untimed antiretroviral drug levels useful predictors of adherence behavior?

Cheryl A Liechty1, Christopher S Alexander, P Richard Harrigan, J David Guzman, Edwin D Charlebois, Andrew R Moss, David R Bangsberg.   

Abstract

We examined cross-sectionally the relationship between untimed drug levels and adherence in 83 individuals. Abnormally low untimed antiretroviral drug levels were sensitive in identifying individuals adherent to 60% or less of medication doses over 3 - 5-week period. An abnormally low drug level was associated with a higher viral load. A single abnormally low untimed antiretroviral drug level can identify an individual with very low adherence at high risk of HIV disease progression and death.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15090840     DOI： 10.1097/00002030-200401020-00017

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  9 in total

Review 1.  Practical and conceptual challenges in measuring antiretroviral adherence.

Authors:  Karina M Berg; Julia H Arnsten
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

2.  Validity of self-report measures in assessing antiretroviral adherence of newly diagnosed, HAART-naïve, HIV patients.

Authors:  April Buscher; Christine Hartman; Michael A Kallen; Thomas P Giordano
Journal:  HIV Clin Trials       Date:  2011 Sep-Oct

3.  Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone.

Authors:  Seth C Kalichman; Christina M Amaral; Heidi Stearns; Denise White; Jody Flanagan; Howard Pope; Chauncey Cherry; Demetria Cain; Lisa Eaton; Moira O Kalichman
Journal:  J Gen Intern Med       Date:  2007-03-28       Impact factor: 5.128

4.  The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes.

Authors:  Lily W Y Tam; Celia K S Chui; Chanson J Brumme; David R Bangsberg; Julio S G Montaner; Robert S Hogg; P Richard Harrigan
Journal:  J Acquir Immune Defic Syndr       Date:  2008-11-01       Impact factor: 3.731

5.  Can urine lamivudine be used to monitor antiretroviral treatment adherence?

Authors:  Agibothu K Hemanth Kumar; Geetha Ramachandran; Periyaiyah Kumar; Vasanthapuram Kumaraswami; Soumya Swaminathan
Journal:  MedGenMed       Date:  2006-12-13

6.  Clinic Attendance for Medication Refills and Medication Adherence amongst an Antiretroviral Treatment Cohort in Uganda: A Prospective Study.

Authors:  Setor Kunutsor; John Walley; Elly Katabira; Simon Muchuro; Hudson Balidawa; Elizabeth Namagala; Eric Ikoona
Journal:  AIDS Res Treat       Date:  2010-12-19

7.  Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.

Authors:  Jessica E Haberer; Jared M Baeten; James Campbell; Jonathan Wangisi; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Christina Psaros; Steven A Safren; Norma C Ware; Katherine K Thomas; Deborah Donnell; Meighan Krows; Lara Kidoguchi; Connie Celum; David R Bangsberg
Journal:  PLoS Med       Date:  2013-09-10       Impact factor: 11.069

8.  Health care provider communication training in rural Tanzania empowers HIV-infected patients on antiretroviral therapy to discuss adherence problems.

Authors:  S Erb; E Letang; T R Glass; A Natamatungiro; D Mnzava; H Mapesi; M Haschke; U Duthaler; B Berger; L Muri; J Bader; C Marzolini; L Elzi; T Klimkait; W Langewitz; M Battegay
Journal:  HIV Med       Date:  2017-03-13       Impact factor: 3.180

9.  Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.

Authors:  Victoria Johnston; Karen Cohen; Lubbe Wiesner; Lynn Morris; Johanna Ledwaba; Katherine L Fielding; Salome Charalambous; Gavin Churchyard; Andrew Phillips; Alison D Grant
Journal:  J Infect Dis       Date:  2013-08-13       Impact factor: 5.226
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.